返回 Agenda
Measuring Impact of Pharmacovigilance in the EU
Session Chair(s)
Saad Shakir, MD, FFPM, FISPE, FRCP
Pharmacovigilance Physician and Pharmacoepidemiologist
ADROITVIGILANCE, United Kingdom
A project which involves PRAC, EMA and ENCePP brought together an extended team of experts to work on ways to measure the impact of pharmacovigilance. The session will provide information on the progress of the project with results.
Learning Objective : 1. Participants should be able to recall the reason why it is important to measure the impact of pharmacovigilance since the legislation was updated in 2012. 2. Participants should be able to explain the methods used to investigate the impact of pharmacovigilance
Speaker(s)
Introduction to the ENCePP Special Interest Group on Impact and an EMA perspective
Xavier Kurz, MD, PHD, MSC
European Medicines Agency, Netherlands
Head of Data Analytics Workstream
Measuring the Impact of Product Withdrawals and Other Major Pharmacovigilance Actions on the Public Health Burden in the EU
Saad Shakir, MD, FFPM, FISPE, FRCP
ADROITVIGILANCE, United Kingdom
Pharmacovigilance Physician and Pharmacoepidemiologist
Measuring the Impact of Pharmacovigilance Activities: Opportunities and Pitfalls
Agnes Kant, MSC
Netherlands Pharmacovigilance Centre, Netherlands
Director